Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
2024 · The Lancet Respiratory Medicine · 54 citations
https://doi.org/10.1016/s2213-2600(24)00324-2